Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A positive feedback loop involving the LINC00346/β-catenin/MYC axis promotes hepatocellular carcinoma development.
|
31691159 |
2020 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Conclusion: Our findings suggest that Bclaf1 affects HCC progression by manipulating c-MYC mRNA stability and that the Hsp90α/Bclaf1/c-Myc axis might be a potential target for therapeutic intervention in HCC.
|
30015413 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
|
30788663 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our data also provide a novel mechanistic understanding of GNMT regulation through MYC in the pathogenesis of HCC.
|
30760754 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Some antigen-expressing <i>MYC;Trp53</i><sup>-/-</sup> HCCs escaped the immune system by upregulating the β-catenin (CTNNB1) pathway.
|
31186238 |
2019 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that HBx and c-MYC are involved in URI1 expression in HCC-B.
|
31739577 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Pathway analysis suggested that putative target genes of these essential miRNAs were involved in HCC-associated signaling pathways, such as Wnt, TGF-β, and Ras; whereas protein-protein network (PPI) analysis demonstrated that some validated target genes of these miRNAs, such as PIK3CA, AKT1, MYC, JUN, SMAD4, and SRC, were hub target genes as they have more counts of interacting protein.
|
31293639 |
2019 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Gene Set Enrichment Analysis (GSEA) indicated that primary HCC samples in the TRMT6 high expression group were enriched for the G2M checkpoint, spermatogenesis, and MYC target genes.
|
31128068 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Since MYC amplification is frequently identified in HCC, co-occurring with EGFR amplification, our findings suggest that targeting EGFR signaling might be essential for JQ1 therapy in advanced HCC.
|
30770740 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In an effort to exploit MYC as a therapeutic target, including in hepatocellular carcinoma (HCC), strategies have been developed on the basis of MYC amplification or gene translocation.
|
30833661 |
2019 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
TXNDC9 promotes hepatocellular carcinoma progression by positive regulation of MYC-mediated transcriptional network.
|
30382079 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we report that a messenger RNA (mRNA) lipid nanoparticle delivering IL-12 (IL-12-LNP) slows down the progression of MYC oncogene-driven HCC.
|
30458889 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In vivo, using liver-specific inducible MYC transgenic mice fed MCD diet, blocking CPT with the pharmacological inhibitor perhexiline decreased apoptosis of intrahepatic CD4<sup>+</sup> T cells and inhibited HCC tumor formation.
|
29795111 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Myc target gene, long intergenic noncoding RNA, Linc00176 in hepatocellular carcinoma regulates cell cycle and cell survival by titrating tumor suppressor microRNAs.
|
28869604 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this study, we performed systemic delivery of a novel lipid nanoparticle (LNP) encapsulating an anti-miR-17 oligonucleotide in a conditional transgenic mouse model of MYC driven HCC.
|
29464015 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro.
|
29698666 |
2018 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells.
|
30007230 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, the expression were low compared with those adjacent to HCC area. c-Myc protein was independently predictive of DFS and OS, and it was negatively correlated with tumor size (P = 0.031), tumor number (P = 0.038), and recurrence (P = 0.001).
|
29690860 |
2018 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Finally, MYC is over-expressed in most of HCCs and is a critical regulator of cellular growth, tumor invasion and metastasis.
|
29507693 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, we investigated the expression and role of FAM83H in 163 human HCCs and further investigated the relationship between FAM83H and oncogene MYC.
|
28607447 |
2017 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Activation of the phosphoinositide 3-kinase-AKT, Yes-associated protein (YAP), and MYC pathways is involved in human liver cancers, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC).
|
28964793 |
2017 |
Liver carcinoma
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma.
|
28697339 |
2017 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Finally, the MYC-positive human hepatocellular carcinoma was characterized by the cytoplasm devoid of lipid accumulation, prominent nucleoli and a higher proliferative activity.
|
28481866 |
2017 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
TP53, MYC) with epigenomic or genomic alternations driving poor prognoses of HCC patients.
|
27006471 |
2016 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
TP53-mutated human HCCs revealed increased AURKA expression and a positive correlation between AURKA and MYC expression.
|
27213815 |
2016 |